Altesa Biosciences, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Altesa Biosciences, Inc.
Finance Watch: A Dozen Deals Add Up To $672m In Biopharma Venture Capital
Ventus Therapeutics raised a $140m series C while Endeavor Biomedicines brought in $101m in series B cash. Also, Twist Bioscience grossed $250m in a follow-on offering, BioMarin raised $110m when it sold a priority review voucher and Nuvectis, TC BioPharm launched IPOs.
Deal Watch: AstraZeneca Out-Licenses Pneumonia Candidate, Obtains STING Inhibitors
Pharma moves Phase III-ready antibody to prevent pneumonia to Aridis, licenses preclinical STING inhibitors from F-star. Sanofi teams with SRI on AI-directed discovery, Biogen licenses BTK inhibitor from InnoCare.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.